Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, often referred to simply as Clinuvel, is an innovative biopharmaceutical company headquartered in Australia. Founded in 2002, Clinuvel has established itself as a leader in the development of treatments for skin disorders, particularly those related to UV exposure and genetic conditions. The company operates primarily in Europe, North America, and Asia, focusing on the research and commercialisation of its unique product, SCENESSE® (afamelanotide), which is designed to protect against phototoxicity.
Clinuvel's commitment to advancing medical science has led to significant milestones, including regulatory approvals in multiple regions. With a strong market position, the company is recognised for its pioneering approach to photoprotection and skin health, setting it apart in the biopharmaceutical industry.
-18 vs industry average
Clinuvel Pharmaceuticals Limited’s score of 20 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Clinuvel Pharmaceuticals Limited?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Clinuvel Pharmaceuticals Limited yet.
Clinuvel Pharmaceuticals Limited's reported carbon emissions
Clinuvel Pharmaceuticals Limited, headquartered in Australia, currently does not report any carbon emissions data, as indicated by the absence of specific figures for Scope 1, Scope 2, and Scope 3 emissions. Consequently, there are no calculated totals or reduction targets available for the company at this time.
In the context of climate commitments, Clinuvel Pharmaceuticals Limited has not outlined any specific reduction initiatives or targets, such as those aligned with the Science Based Targets initiative (SBTi). The company does not appear to have made any public climate pledges or commitments to reduce its carbon footprint.
As the pharmaceutical industry increasingly focuses on sustainability, Clinuvel's lack of reported emissions data and climate commitments may reflect a broader trend within the sector, where many companies are still in the early stages of developing comprehensive climate strategies.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Clinuvel Pharmaceuticals Limited’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Clinuvel Pharmaceuticals Limited yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Clinuvel Pharmaceuticals Limited
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project